Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Genscript Biotech ( (HK:1548) ) is now available.
Genscript Biotech Corporation has announced a significant expected increase in profit before tax for the first half of 2025, compared to the same period in 2024. This growth is primarily driven by a substantial rise in license revenue, particularly from LaNova Medicines Ltd., and a decrease in non-cash fair value loss from its preferred shares. The announcement highlights the company’s strategic positioning and ability to leverage its diversified business model and technological capabilities, potentially impacting its stakeholders positively.
More about Genscript Biotech
Genscript Biotech Corporation, incorporated in the Cayman Islands, operates in the biotechnology industry. The company focuses on providing innovative technologies and products, including gene synthesis, peptide synthesis, protein production, and antibody development services. It is engaged in the global value chain distribution through its advanced technology and platforms.
YTD Price Performance: 70.73%
Average Trading Volume: 25,678,619
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.44B
For detailed information about 1548 stock, go to TipRanks’ Stock Analysis page.